ArticleJournal of experimental & clinical cancer research : CR2025
tRNA-derived fragment tRF-24 drives CELF1 phase separation to promote oncogenic splicing in esophageal squamous cell carcinoma.
Article in Journal of experimental & clinical cancer research : CR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
rationaleEsophageal squamous cell carcinoma (ESCC) is characterized by poor prognosis. tRNA-derived fragments (tRFs), a novel class of non-coding RNAs generated by tRNA cleavage, have emerged as key regulators of cancer development. However, the functional landscape of tRFs remains underexplored in ESCC. We here identified tRF-24-RPM8309M2S (tRF-24), a 5' tRF derived from mature tRNA
methodsThe public GSE207635 dataset from Gene Expression Omnibus (GEO) database was analyzed to identify tsRNAs involved in ESCC progression. The clinical significance of tRF-24 was investigated in samples from 96 ESCC patients. CUGBP Elav-like family member 1 (CELF1) was validated as a tRF-24 interactor through RNA pull-down assays. CCK-8 and transwell assays were applied to measure malignant cell phenotypes. mCherry-GFP-LC3 reporter assay was performed to examine the autophagy. Colocalization between LC3 and mitochondria was employed to detect mitophagy. Immunofluorescent and colony formation assay were conducted to assess the impact of DNA damage repair and cisplatin resistance in ESCC. Extracellular acidification rate (ECAR), lactate production and glucose consumption were performed to analyze changes in glycolysis. Fluorescence recovery after photobleaching (FRAP) was adopted to evaluate CELF1 phase separation. Additionally, RNA sequencing and alternative splicing analyses were conducted to determine global transcriptome alterations following tRF-24 or CELF1 overexpression.
resultsOur findings demonstrate that tRF-24 is significantly upregulated in tumor samples and is associated with poorer survival of ESCC patients. Depletion of tRF-24 suppresses malignant cell phenotypes in ESCC cells both in vitro and in vivo. Mechanistically, tRF-24 binds to the Ser28 residue of CELF1, inhibiting AKT1-mediated phosphorylation at this site, which facilitates CELF1 nuclear translocation and subsequent liquid-liquid phase separation (LLPS) formation. These CELF1-enriched nuclear condensates potently regulate the alternative splicing of BIN1 and BECN1 pre-mRNAs, generating pro-oncogenic BIN1-L and pro-autophagic/mitophagic BECN1-α isoforms that collectively enhance tumor malignancy by promoting tumor cell EMT, DNA damage repair, cisplatin resistance and glycolysis. Targeting tRF-24 with an antagomir significantly suppresses tumor progression in ESCC xenograft models, highlighting its therapeutic potential.
conclusionsOur findings establish tRF-24 as a promising therapeutic target in the comprehensive treatment of ESCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.